Commission Implementing Regulation (EU) 2023/1446 of 12 July 2023 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances 2,5-dichlorobenzoic acid methylester, acetic acid, aluminium ammonium sulphate, aluminium phosphide, aluminium silicate, calcium carbide, cymoxanil, dodemorph, ethylene, extract from tea tree, fat distillation residues, fatty acids C7-C20, flonicamid (IKI-220), gibberellic acid, gibberellins, halosulfuron-methyl, hydrolysed proteins, iron sulphate, magnesium phosphide, maltodextrin, metamitron, plant oils/clove oil, plant oils/rape seed oil, plant oils/spear mint oil, pyrethrins, sulcotrione, tebuconazole and urea (Text with EEA relevance)

• CELEX: Implementing Regulation (EU) 2023/1446
• Articles: 3

Article 1

The Annex to Implementing Regulation (EU) No 540/2011 is amended in accordance with the Annex to this Regulation.

Article 2

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union .

Schedules & Appendices

ANNEX

ANNEX

The Annex to Implementing Regulation (EU) No 540/2011 is amended as follows:

1.

Part A is amended as follows:

(1)

in the sixth column, expiration of approval, of row 218, Acetic acid, the date is replaced by ‘30 November 2026’;

(2)

in the sixth column, expiration of approval, of row 219, Aluminium ammonium sulphate, the date is replaced by ‘15 December 2024’;

(3)

in the sixth column, expiration of approval, of row 220, Aluminium silicate, the date is replaced by ‘15 December 2024’;

(4)

in the sixth column, expiration of approval, of row 223, Calcium carbide, the date is replaced by ‘30 November 2026’;

(5)

in the sixth column, expiration of approval, of row 227, Ethylene, the date is replaced by ‘30 November 2026’;

(6)

in the sixth column, expiration of approval, of row 228, Extract from tea tree, the date is replaced by ‘31 January 2026’;

(7)

in the sixth column, expiration of approval, of row 229, Fat distillation residues, the date is replaced by ‘15 December 2024’;

(8)

in the sixth column, expiration of approval, of row 230, Fatty acids C7 to C20, the date is replaced by ‘15 December 2024’;

(9)

in the sixth column, expiration of approval, of row 232, Gibberellic acid, the date is replaced by ‘15 July 2025’;

(10)

in the sixth column, expiration of approval, of row 233, Gibberellins, the date is replaced by ‘15 July 2025’;

(11)

in the sixth column, expiration of approval, of row 234, Hydrolysed proteins, the date is replaced by ‘15 April 2025’;

(12)

in the sixth column, expiration of approval, of row 235, Iron sulphate, the date is replaced by ‘30 November 2026’;

(13)

in the sixth column, expiration of approval, of row 241, Plant oils/clove oil, the date is replaced by ‘31 January 2026’;

(14)

in the sixth column, expiration of approval, of row 242, Plant oils/rape seed oil, the date is replaced by ‘15 December 2024’;

(15)

in the sixth column, expiration of approval, of row 243, Plant oils/spear mint oil, the date is replaced by ‘31 January 2026’;

(16)

in the sixth column, expiration of approval, of row 246, Pyrethrins, the date is replaced by ‘15 June 2026’;

(17)

in the sixth column, expiration of approval, of row 257, Urea, the date is replaced by ‘30 November 2026’;

(18)

in the sixth column, expiration of approval, of row 260, Aluminium phosphide, the date is replaced by ‘30 November 2026’;

(19)

in the sixth column, expiration of approval, of row 262, Magnesium phosphide, the date is replaced by ‘30 November 2026’;

(20)

in the sixth column, expiration of approval, of row 263, Cymoxanil, the date is replaced by ‘15 August 2026’;

(21)

in the sixth column, expiration of approval, of row 264, Dodemorph, the date is replaced by ‘30 November 2026’;

(22)

in the sixth column, expiration of approval, of row 265, 2,5-Dichlorobenzoic acid methylester, the date is replaced by ‘30 November 2026’;

(23)

in the sixth column, expiration of approval, of row 266, Metamitron, the date is replaced by ‘30 November 2026’;

(24)

in the sixth column, expiration of approval, of row 267, Sulcotrione, the date is replaced by ‘30 November 2026’;

(25)

in the sixth column, expiration of approval, of row 268, Tebuconazole, the date is replaced by ‘15 August 2026’;

(26)

in the sixth column, expiration of approval, of row 305, Flonicamid (IKI-220), the date is replaced by ‘30 November 2026’;

2.

Part B is amended as follows:

(1)

in the sixth column, expiration of approval, of row 35, Halosulfuron-methyl, the date is replaced by ‘31 March 2025’;

(2)

in the sixth column, expiration of approval, of row 44, Maltodextrin, the date is replaced by ‘28 February 2026’.